StocksMedium•13 November 2026•
1 min read
Altimmune Stock Drops Following Wider-Than-Expected Q3 Losses
Key Facts
1Altimmune reported a wider-than-expected Q3 loss driven by rising research and development expenses.
2The company is advancing its drug pemvidutide across MASH, AUD, and ALD programs.
Altimmune reported a wider-than-expected Q3 loss driven by rising research and development expenses. According to Zacks, the company is advancing its drug pemvidutide across clinical programs for metabolic dysfunction-associated steatohepatitis (MASH) and alcohol use disorders.
Altimmune stock closed at $1.61 on November 12, 2026, as concerns over operational costs and funding weighed on investor sentiment. During the session, the stock traded between a low of $1.6 and a high of $1.9.